Haisco receives approval for HSK44459 clinical trials

Haisco Pharmaceutical Group (SZSE:002653) announced that its subsidiary, Shanghai Haisco Shengnuo Pharmaceutical Technology, has received approval from the National Medical Products Administration for clinical trials of HSK44459 tablets for two new indications: psoriasis and atopic dermatitis. This approval, based on a review completed in December 2024, allows Haisco to proceed with clinical trials for this innovative drug, categorized as a Class 1 chemical drug. HSK44459, independently developed by Haisco, is a targeted therapy with potential advantages over existing treatments. The company has already completed Phase I clinical trials for HSK44459 for interstitial lung disease. Haisco cautions investors about the risks inherent in drug development.